IQVIA Holdings Inc. $IQV Shares Acquired by Callan Family Office LLC

Callan Family Office LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 342.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,227 shares of the medical research company’s stock after acquiring an additional 4,819 shares during the period. Callan Family Office LLC’s holdings in IQVIA were worth $981,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in IQV. Brighton Jones LLC increased its position in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of IQVIA during the 1st quarter worth approximately $482,000. GAMMA Investing LLC lifted its position in shares of IQVIA by 56.3% during the 1st quarter. GAMMA Investing LLC now owns 2,197 shares of the medical research company’s stock worth $387,000 after buying an additional 791 shares during the last quarter. Fifth Third Bancorp raised its position in IQVIA by 21.5% in the 1st quarter. Fifth Third Bancorp now owns 16,013 shares of the medical research company’s stock valued at $2,823,000 after purchasing an additional 2,834 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock valued at $2,338,000 after purchasing an additional 3,398 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on IQV. Barclays upped their price target on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the stock from $195.00 to $235.00 in a research note on Thursday. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, UBS Group increased their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $236.45.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

NYSE:IQV opened at $198.35 on Monday. The firm has a market cap of $33.72 billion, a price-to-earnings ratio of 28.70, a price-to-earnings-growth ratio of 2.18 and a beta of 1.32. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company’s 50-day moving average is $189.02 and its two-hundred day moving average is $168.11. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $237.34.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.